rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CADL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Candel Therapeutics (CADL) Stock Fair Value Moves Lower After Analysts Cut Targets
      Nov 15Yahoo FinanceCADL
      Candel Therapeutics stock price target cut to $19 by Stifel on BLA delay
      Nov 13Investing.comCADLSF
      Candel Therapeutics stock plummets 35% on prostate cancer BLA delay
      Nov 13Yahoo FinanceCADL
      Why is Candel Therapeutics stock collapsing today?
      Nov 13Investing.comCADL
      Candel Therapeutics Shares Tumble 39% After-Hours: Here's Why
      Nov 13BenzingaCADL
      CADL Stock Tumbles 38% After-Hours As Candel Pushes Prostate Cancer FDA Application Timeline To Mid-2027
      Nov 12Yahoo FinanceCADL
      Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
      Nov 12Yahoo FinanceCADL
      Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
      Nov 6Yahoo FinanceCADL
      Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
      Nov 5Yahoo FinanceCADL
      Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 2Yahoo FinanceCADL
      Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

      NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that a late-breaking abstract from its phase 2 PrTK05 clinical trial evaluating aglatimagene besadenovec (aglatimagene) in localized prostate cancer has been accepted for poster presentation at the Society for Immunotherap

      Oct 29Yahoo FinanceCADL
      Candel Therapeutics to Present at November Investor Conferences

      NEEDHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in November 2026. Key

      Oct 27Yahoo FinanceCADL
      Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
      Oct 22Yahoo FinanceCADL
      Jefferies initiates Candel Therapeutics stock with buy rating on prostate cancer data
      Oct 22Investing.comCADL
      Candel Therapeutics to Present at the SITC 2026 Annual Meeting
      Oct 2Yahoo FinanceCADL
      H.C. Wainwright reiterates Candel Therapeutics stock rating on trial data
      Oct 2Investing.comCADL
      Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on September 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to 4 new employees, stock options to purchase an aggregate of 85,900 shares of the Company’s common stock, with a pe

      Oct 1Yahoo FinanceCADL
      Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

      Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these findings provide mechanistic support for the long-term clinical outcomes, including disease-free survival and prolonged time to biochemical failure, time to metastasis, and time to salvage anti-cancer therapy, observed in this patient populationBiodistribution and shedding data from the PrTK05 phase 2 tria

      Sep 30Yahoo FinanceCADL
      Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

      AI-enabled digital pathology analysis shows aglatimagene significantly increased lymphocyte infiltration and immune engagement with tumor cells compared to standard-of-care radiotherapy alone two years after treatment NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the

      Sep 30Yahoo FinanceCADL
      CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’
      Sep 30Yahoo FinanceCADL
      Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 (CADL)
      Sep 22Seeking AlphaCADL
      H.C. Wainwright Remains a Buy on Candel Therapeutics (CADL)

      Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailCADL
      Why is Candel Therapeutics stock surging today?
      Sep 21Investing.comCADL
      Candel Therapeutics Shares Rise After BofA Upgrade

      Candel Therapeutics (CADL) shares rose 3.9% in Monday trading after BofA upgraded the stock to buy f

      Sep 21Yahoo FinanceCADL
      BofA upgrades Candel Therapeutics stock rating on prostate cancer progress
      Sep 21Investing.comCADL
      Candel Therapeutics stock jumps on BofA upgrade to buy
      Sep 21Investing.comCADL
      BofA Upgrades Candel Therapeutics to Buy From Neutral, Price Target is $18
      Sep 21Yahoo FinanceCADL
      This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
      Sep 21BenzingaCADLAMHINVHMAC
      The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux

      Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.

      Sep 16Yahoo FinanceCADL
      Candel Therapeutics at H.C. Wainwright conference: prostate cancer push
      Sep 15Investing.comCADL
      Candel Therapeutics Insider Sold Shares Worth $3,160,783, According to a Recent SEC Filing
      Sep 14Yahoo FinanceCADL
      Candel Therapeutics CEO Tak sells $3.16m in CADL stock
      Sep 12Investing.comCADL
      Candel Therapeutics at Cantor global healthcare conference: prostate cancer push
      Sep 10Investing.comCADL
      Candel Therapeutics appoints Martine Zimmermann to board
      Sep 10Investing.comCADL
      Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

      Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Martine Zimmermann, PharmD, to the

      Sep 10Yahoo FinanceCADL
      Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on August 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 31,400 shares of the Company’s common stock, with a pe

      Sep 1Yahoo FinanceCADL
      Candel Therapeutics stock hits 52-week high at $13.96
      Aug 27Investing.comCADL
      Candel Therapeutics to Present at September Investor Conferences

      NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in September 2026. Ke

      Aug 26Yahoo FinanceCADL
      Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed?

      Candel Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$38.91 million, up sharply from US$4.8 million a year earlier, with basic and diluted loss per share from continuing operations of US$0.52 versus US$0.09. For the first half of 2026, the company moved from net income of US$2.58 million a year ago to a net loss of US$47.77 million, highlighting a pronounced reversal in its recent financial performance. Next, we will examine how this sharp widening of losses...

      Aug 21Yahoo FinanceCADL

      This is the newest page. Registered accounts read further back.